keyword
MENU ▼
Read by QxMD icon Read
search

pneumococcal conjugate vaccine

keyword
https://www.readbyqxmd.com/read/28531208/phylogenetic-analysis-of-emergent-streptococcus-pneumoniae-serotype-22f-causing-invasive-pneumococcal-disease-using-whole-genome-sequencing
#1
Walter H B Demczuk, Irene Martin, Linda Hoang, Paul Van Caeseele, Brigitte Lefebvre, Greg Horsman, David Haldane, Jonathan Gubbay, Sam Ratnam, Gregory German, Jennifer Daley Bernier, Lori Strudwick, Allison McGeer, George G Zhanel, Gary Van Domselaar, Morag Graham, Michael R Mulvey
Since implementation of the 13-valent polyvalent conjugate vaccine (PCV13) in Canada during 2010, the proportion of PCV13 serotypes causing invasive pneumococcal disease (IPD) has declined from 55% (n = 1492) in 2010 to 31% (n = 764) in 2014. A concurrent increase of non-PCV13 serotypes has occurred and 22F has become the most prevalent serotype in Canada increasing from 7% (n = 183) to 11% (n = 283). Core single nucleotide variant phylogenetic analysis was performed on 137 Streptococcus pneumoniae serotype 22F isolates collected across Canada from 2005-2015...
2017: PloS One
https://www.readbyqxmd.com/read/28526059/severe-polyserositis-induced-by-the-13-valent-pneumococcal-conjugate-vaccine-a-case-report
#2
Pierre Tawfik, Elie Gertner, Charlene E McEvoy
BACKGROUND: The United States Advisory Committee on Immunization Practices recommends administration of the 13-valent pneumococcal conjugate vaccine in series with the 23-valent pneumococcal polysaccharide vaccine for prevention of pneumonia in the elderly. Reports of autoimmune or auto-inflammatory diseases as a result of pneumococcal vaccination, especially pneumococcal conjugate vaccine, are extremely rare. CASE PRESENTATION: We present a case of severe serositis in a 75-year-old Caucasian woman complicated by pericardial and pleural effusions in the setting of recent 13-valent pneumococcal conjugate vaccine vaccination and no other obvious etiology...
May 20, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28518018/penicillin-resistance-of-nonvaccine-type-pneumococcus-before-and-after-pcv13-introduction-united-states
#3
Cheryl P Andam, Colin J Worby, Ryan Gierke, Lesley McGee, Tamara Pilishvili, William P Hanage
Introduction of 13-valent pneumococcal conjugate vaccine in the United States was not associated with a significant change in prevalence of penicillin resistance in nonvaccine type serotypes because of the variable success of highly resistant serotypes. Differences in regional serotype distribution and serotype-specific resistance contributed to geographic heterogeneity of penicillin resistance.
June 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28516866/invasive-serotype-35b-pneumococci-including-an-expanding-serotype-switch-lineage-united-states-2015-2016
#4
Sopio Chochua, Benjamin J Metcalf, Zhongya Li, Hollis Walker, Theresa Tran, Lesley McGee, Bernard Beall
We used whole-genome sequencing to characterize 199 nonvaccine serotype 35B pneumococcal strains that caused invasive pneumococcal disease (IPD) in the United States during 2015-2016 and related these findings to previous serotype 35B IPD data obtained by Active Bacterial Core surveillance. Penicillin-nonsusceptible 35B IPD increased during post-pneumococcal 7-valent conjugate vaccine years (2001-2009) and increased further after implementation of pneumococcal 13-valent conjugate vaccine in 2010. This increase was caused primarily by the 35B/sequence type (ST) 558 lineage...
June 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28516842/serotype-distribution-antimicrobial-resistance-and-prevalence-of-pilus-islets-in-pneumococci-following-the-use-of-conjugate-vaccines
#5
Mitsuyo Kawaguchiya, Noriko Urushibara, Meiji Soe Aung, Masaaki Shinagawa, Satoshi Takahashi, Nobumichi Kobayashi
PURPOSE: In Japan, the 7-valent pneumococcal vaccine (PCV7) was introduced in 2010 and, in 2013, the PCV7 was replaced with the 13-valent pneumococcal vaccine (PCV13). This study was conducted to investigate serotypes, antimicrobial resistance and prevalence of pilus islets in pneumococcal isolates from inpatients in a Japanese tertiary hospital. METHODOLOGY: From April 2011 to February 2016, 151 isolates [95 (18 children, 77 adults) and 56 (19 children, 37 adults) in the PCV7 and PCV13 periods, respectively] were collected...
May 2017: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/28510985/changing-diagnosis-coding-routines-may-confound-the-results-of-longitudinal-childhood-pneumonia-studies
#6
M Eriksson, A Nilsson, R Bennet
AIM: This Swedish study compared the discharge diagnosis codes used for children up to the age of five hospitalised for acute lower respiratory tract infections before and after the introduction of the pneumococcal conjugate vaccine in 2007. METHODS: The International Classification of Diseases - 10(th) revision codes were used. We compared the discharge diagnosis codes at the Astrid Lindgren Children's Hospital from 1 July 2005 to 30 June 2007 (n=1,127) and 1 July 2011 to 30 June 2013 (n=1,240) in relation to the diagnostic methods used...
May 16, 2017: Acta Paediatrica
https://www.readbyqxmd.com/read/28510699/invasive-pneumococcal-disease-in-infants-aged-0-60-days-in-the-united-states-in-the-13-valent-pneumococcal-conjugate-vaccine-era
#7
Liset Olarte, William J Barson, John S Bradley, Tina Q Tan, Philana Ling Lin, José R Romero, Laurence B Givner, Jill A Hoffman, Kristina G Hultén, Edward O Mason, Sheldon L Kaplan
We identified 53 infants aged 0-60 days with invasive pneumococcal disease (IPD) at 8 children's hospitals in the United States (2005-2015). After the introduction of 13-valent pneumococcal conjugate vaccine (PCV13), IPD caused by PCV13 serotypes decreased ~30% providing some evidence of indirect protection. However, approximately 60% of IPD was still caused by PCV13 serotypes.
May 16, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/28508419/case-control-study-shows-that-neonatal-pneumococcal-meningitis-cannot-be-distinguished-from-group-b-streptococcus-cases
#8
Alexandra Arfi, Robert Cohen, Emmanuelle Varon, Stéphane Béchet, Stéphane Bonacorsi, Corinne Levy
AIM: Streptococcus pneumoniae (S. pneumoniae) is sometimes implicated in neonatal bacterial meningitis. This study described the demographic, clinical and biological features of neonatal S. pneumoniae meningitis and compared pneumococcal and group B streptococcal (GBS) neonatal meningitis. METHODS: We conducted a case-control study that compared neonates, aged one to 28 days with S. pneumoniae meningitis or GBS meningitis. Each case with S. pneumoniae was randomly matched to four control patients with GBS by age group and study year...
May 16, 2017: Acta Paediatrica
https://www.readbyqxmd.com/read/28503278/conjugate-and-23-valent-pneumococcal-polysaccharide-booster-vaccination-in-asplenic-patients-with-thalassemia-major-a-randomized-clinical-trial-study
#9
Mohammad Sadegh Rezai, Javad Ghaffari, Mohammadreza Mahdavi, Amir Bahari, Shahram Ala
BACKGROUND: Pneumococcal vaccine provides protection against invasive pneumococcal disease in population at risk. This study was conducted to compare the antibody response to 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in patients with thalassemia major. METHODS: A randomized cross-over clinical trial was performed on 50 asplenic patients with thalassemia major who referred to thalassemia center at Bouali Sina Hospital, Sari, Iran from 2013 to 2014...
2017: Caspian Journal of Internal Medicine
https://www.readbyqxmd.com/read/28501455/exploring-the-acceptability-of-the-available-pneumococcal-conjugate-vaccines-in-canadian-health-care-professionals-and-immunization-experts
#10
Melissa Berman, Eve Dubé, Caroline Quach
BACKGROUND: In children, the 13 and 10-valent pneumoccocal conjugate vaccines (PCV13/10) are currently approved for the prevention of invasive pneumococcal disease (IPD). Acceptability is a key consideration in the implementation of a vaccine program and it is recognized that health professional's attitudes and opinions towards vaccines are independent predictors of the success of an immunization program. We aimed to survey the beliefs and attitudes for the two available PCVs in health care professionals and immunization experts...
June 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28498857/cost-effectiveness-of-pneumococcal-vaccination-strategies-for-the-elderly-in-korea
#11
Jung Yeon Heo, Yu Bin Seo, Won Suk Choi, Jacob Lee, Ji Yun Noh, Hye Won Jeong, Woo Joo Kim, Min Ja Kim, Hee Young Lee, Joon Young Song
BACKGROUND: Although the 13-valent pneumococcal conjugate vaccine (PCV13) showed good efficacy against pneumococcal disease in the the CAPiTA trial, the 23-valent pneumococcal polysaccharide vaccination (PPSV23) program has been ongoing for older adults aged ≥ 65 years in Korea since May of 2013. This study aimed to evaluate the cost-effectiveness of the current vaccination strategy (a single-dose PPSV23 vaccination) compared to a single-dose PCV13 vaccination and sequential PCV13-PPSV23 vaccinations in the elderly population aged ≥ 65 years...
2017: PloS One
https://www.readbyqxmd.com/read/28498097/the-asplenic-patient-post-insult-immunocompetence-infection-and-vaccination
#12
Brandon Dionne, Walter Dehority, Meghan Brett, Thomas R Howdieshell
BACKGROUND: Splenic injury can occur through multiple mechanisms and may result in various degrees of residual immunocompetence. Functionally or anatomically asplenic patients are at higher risk for infection, particularly with encapsulated bacteria. Vaccination is recommended to prevent infection with these organisms; however, the recommendations are routinely updated, and vaccine selection and timing are complex. METHODS: Review of the pertinent English-language literature, including the recommendations of the U...
May 12, 2017: Surgical Infections
https://www.readbyqxmd.com/read/28497715/health-maintenance-deficits-in-a-fully-insured-population-of-adolescents-with-chronic-medical-conditions
#13
Rebecca Sainato, Michelle Flores, Allison Malloy, Casey Geaney, Michael Rajnik, Martin Ottolini, Martin Weisse
The current national monitoring of routine wellness care and vaccine uptake does not provide data on health maintenance among pediatric populations with chronic medical conditions. In this case-control study that analyzes wellness visits and vaccine uptake among adolescents, ages 16 to 18 years, we identified 938 without (controls) and 74 with (cases) 1 of 12 specific chronic medical conditions. The PPSV23 (23-valent pneumococcal polysaccharide vaccine) is recommended by the Advisory Committee on Immunization Practices for these 12 conditions and served as a measure of uptake for medically indicated vaccines...
June 2017: Clinical Pediatrics
https://www.readbyqxmd.com/read/28494193/long-term-trends-in-invasive-pneumococcal-disease-in-manitoba-canada
#14
Salaheddin M Mahmud, Hasantha Sinnock, Luiz C Mostaço-Guidolin, Gurpreet Pabla, Aleksandra K Wierzbowski, Songul Bozat-Emre
Invasive pneumococcal disease (IPD) remains a significant public health problem in Manitoba, Canada although publically-funded pneumococcal conjugate (PCV7 and PCV13) and polysaccharide (PPV23) vaccination programs exist. We analyzed routine surveillance and administrative health data to examine trends in IPD rates as these vaccines were introduced. Data on all individuals with a laboratory-confirmed diagnosis of IPD between 2001 and 2014 were obtained from the provincial Communicable Diseases Surveillance database and linked with Manitoba's provincial immunization registry and physician and hospital databases...
May 11, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28488145/anti-pneumococcal-vaccine-induced-cellular-immune-responses-in-post-traumatic-splenectomized-individuals
#15
Djursun Karasartova, Umut Gazi, Ozgur Tosun, Ayse S Gureser, Ibrahim T Sahiner, Mete Dolapci, Aysegul T Ozkan
PURPOSE: Splenectomy is associated with increased risk of overwhelming post-splenectomy infections despite proper anti-pneumococcal vaccination. As most studies concentrated on vaccination-induced humoral immunity, the cellular immune responses triggered in splenectomized patients are not yet well studied. The present study aims to investigate this area as it can contribute to the development of more effective vaccination strategies. METHODS: Five healthy and 14 splenectomized patients were vaccinated with pneumococcal conjugate polysaccharide vaccine (PCV) followed by pneumococcal polysaccharide vaccine according to the guidelines established by Advisory Committee on Immunization Practices...
May 2017: Journal of Clinical Immunology
https://www.readbyqxmd.com/read/28487056/polysaccharide-conjugate-vaccine-protein-carriers-as-a-neglected-valency-potential-and-limitations
#16
REVIEW
Michael Bröker, Francesco Berti, Joerg Schneider, Ivo Vojtek
The development of vaccines against polysaccharide-encapsulated pathogens (e.g. Haemophilus influenzae type b, pneumococci, meningococci) is challenging because polysaccharides do not elicit a strong and long-lasting immune response (i.e. T-cell independent). This can be overcome by conjugating the polysaccharide to a protein carrier (e.g. tetanus toxoid, cross-reacting material 197 [CRM]), which vastly improves the immune response and induces memory to the polysaccharide (T-cell dependent). Although it is well documented that protein carriers additionally induce an immune response against themselves, this potential "additional valency" has so far not been recognized...
June 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28486544/serotype-distribution-of-streptococcus-pneumoniae-causing-invasive-disease-in-children-in-the-post-pcv-era-a-systematic-review-and-meta-analysis
#17
Evelyn Balsells, Laurence Guillot, Harish Nair, Moe H Kyaw
BACKGROUND: Routine immunisation with pneumococcal conjugate vaccines (PCV7/10/13) has reduced invasive pneumococcal disease (IPD) due to vaccine serotypes significantly. However, an increase in disease due to non-vaccine types, or serotype replacement, has been observed. Serotypes' individual contributions to IPD play a critical role in determining the overall effects of PCVs. This study examines the distribution of pneumococcal serotypes in children to identify leading serotypes associated with IPD post-PCV introduction...
2017: PloS One
https://www.readbyqxmd.com/read/28483246/comparison-of-first-year-of-life-acute-otitis-media-admissions-before-and-after-the-13-valent-pneumococcal-conjugate-vaccine
#18
Tal Marom, Ofer Israel, Haim Gavriel, Jacob Pitaro, Ali Abo Baker, Ephraim Eviatar
BACKGROUND: Acute otitis media (AOM) is a common childhood infection, which is usually managed in the outpatient setting. Yet, the more severe cases are referred for inpatient treatment. We hypothesized that pneumococcal conjugate vaccines (PCVs), administered during the first year of life, would decrease AOM admissions rate in this age group. We studied the characteristics of infants admitted with AOM and acute mastoiditis (AM) in the PCV13 era, routinely given from November 2010 to all infants...
June 2017: International Journal of Pediatric Otorhinolaryngology
https://www.readbyqxmd.com/read/28482054/safety-of-vaccinations-in-patients-with-cryopyrin-associated-periodic-syndromes-a-prospective-registry-based-study
#19
Veronika K Jaeger, Hal M Hoffman, Tom van der Poll, Hugh Tilson, Julia Seibert, Antonio Speziale, Guido Junge, Kristina Franke, Eleni Vritzali, Philip N Hawkins, Jasmin Kuemmerle-Deschner, Ulrich A Walker
Objectives.: Pneumococcal, tetanus and influenza vaccinations are recommended for patients with cryopyrin-associated periodic syndromes (CAPS) when treated with immunosuppressive medication. The aim of this publication is to report the safety of pneumococcal and other vaccinations in CAPS patients. Methods.: All CAPS patients followed in the β-CONFIDENT (Clinical Outcomes and Safety Registry study of Ilaris patients) registry were analysed if they had received a vaccination...
May 6, 2017: Rheumatology
https://www.readbyqxmd.com/read/28482004/imputing-direct-and-indirect-vaccine-effectiveness-of-childhood-pneumococcal-conjugate-vaccine-against-invasive-disease-by-surveying-temporal-changes-in-nasopharyngeal-pneumococcal-colonization
#20
Susan A Nzenze, Shabir A Madhi, Tinevimbo Shiri, Keith P Klugman, Linda de Gouveia, David P Moore, Alan S Karstaedt, Stefano Tempia, Marta C Nunes, Anne von Gottberg
The limited capabilities in most low-middle income countries to study the bebfit of pneumococcal conjugate vaccine (PCV) against invasive pneumococcal disease (IPD), calls for alternate strategies to assess this. We used a mathematical model, to predict the direct and indirect effectiveness of PCV by analyzing serotype specific colonization prevalence and IPD incidence prior to and following childhood PCV immunization in South Africa. We analyzed IPD incidence from 2005-2012 and colonization studies undertaken in HIV-uninfected and HIV-infected child-mother dyads from 2007-2009 (pre-PCV era), in 2010 (7-valent PCV era) and 2012 (13-valent PCV era)...
May 6, 2017: American Journal of Epidemiology
keyword
keyword
112012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"